IMMUNITYBIO INC (IBRX)
Health Care · biotechnology · NASDAQ
ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients.
What IMMUNITYBIO INC does
ImmunityBio is a clinical-stage biotechnology company focused on developing therapies and vaccines that activate the human immune system to fight cancers and infectious diseases. Its core technology, the Cancer BioShield platform, utilizes multiple therapeutic modalities, including immunotherapy, cell therapy, and vaccines, to induce broad-based immune responses. The company's lead product, ANKTIVA, is an IL-15 superagonist approved for specific bladder cancer indications.
Themes: immunotherapy, cell therapy, oncology, cancer vaccines, natural killer (NK) cell therapy, infectious disease research
Fundamentals
- Price$9.91 as of 2026-10-08 close
- Market cap$10.5B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+291.7% 2025-10-08 close $2.53 → 2026-10-08 close $9.91
- P/En/a negative earnings
- Net margin-310.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+192.9% as of 2026-09-03
- Revenue CAGR (3y)+678.6% SEC XBRL
- Beta1.58 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How IBRX compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IBRX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: no valuation data.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How IMMUNITYBIO INC looks technically
IMMUNITYBIO INC (IBRX) is trading 36.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 174 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 20.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 36.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +36.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.24 | $8.24 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.24 | $7.24 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 8.76. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 174 trading days ago — a "golden cross", a bullish long-term signal | 174 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with buyers in control | 42.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($8.26 to $10.81) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 64.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $12.43 | $12.43 |
|---|---|---|
| From the 52-week high | it is 20.3% below its 52-week high (its highest price of the past year) | -20.3% |
| Above the 52-week low | it is 408.2% above its 52-week low (its lowest price of the past year) | +408.2% |
| Below the 52-week high | it is 20.3% below its highest point of the past year | 20.3% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $45.42 (set on 2021-02-22) | $45.42 |
| Given back of the 52-week move | over the past year its closes ranged ($1.98 to $11.55), and it has given back roughly a quarter of its rise from last year’s low — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.33 to $5.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.1% |
| From the all-time high | it is 78.2% below its all-time high | -78.2% |
| Nearest price level | it is trading 3.7% above a support level at $9.54 — a price it turned at three times since 2026-03-23, most recently on 2026-09-22. Since 2024-10-08 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.7% |
| All-time low | its lowest closing price on record is $0.93 (set on 2018-12-26) | $0.93 |
| Above the all-time low | it is 965.6% above its all-time low | +965.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6212 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6212 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.46 and $10.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.46 – $8.94 – $10.42 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 4.3 daily ranges above its 200-day average price (36.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.87× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.2% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 15 sessions ago and has not traded back through the level it left behind at 7.91 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 4.6% gap up opened on 2026-10-05 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.27% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 18.5 percentage points (the stock gained 19.5% while the market gained 1.0%) | +18.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.8 percentage points (the stock gained 12.6% while the market gained 3.8%) | +8.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 22.5 percentage points (the stock gained 40.0% while the market gained 17.5%) | +22.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 276.7 percentage points (the stock gained 291.7% while the market gained 15.0%) | +276.7% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.2% of the share price. | +22.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.52 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +31.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $8.55 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | +16.0% |
Double bottom, bullish — broke out · entry $9.44 · 79 sessions in
Price levels it has turned at before
IBRX last closed at $9.91 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.54 | Support | 3.7% below the last close | turned there three times · 2026-03-23 to 2026-09-22 |
| $8.63 | Support | 12.9% below the last close | turned there three times · 2026-04-21 to 2026-05-20 |
| $6.69 | Support | 32.5% below the last close | turned there three times · 2026-04-29 to 2026-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $8.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $8.76 and $9.05 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · beating the market · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$12.75 range $12.00 – $15.00; median $12.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IBRX
- Consensus EPS estimate-$0.05 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$0.05, on 2026-09-04, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependency on additional financing to fund ongoing operations and commercialization efforts.","Risk of failing to obtain or maintain regulatory approvals for additional indications of ANKTIVA or product candidates.","Dependence on third-party contract manufacturing organizations (CMOs) for product production."]
What changed in the latest 10-Q
AI-assisted comparison of IBRX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added 'globally in NMIBC, NSCLC or other indications' to first forward-looking statement about commercializing ANKTIVA (2026-05-07 filing)
- Added reference to 'Cancer BioShield platform (comprises multiple therapeutic modalities to activate immune response)' in expectations regarding potential benefits (2026-05-07 filing)
- Added 'NK-CAR (t-haNK™)' to list of clinical trials data expected to support product candidate development (2026-05-07 filing)
- Added 'with CIS, with papillary tumors and NSCLC' to indications for which ANKTIVA incremental approvals are sought (2026-05-07 filing)
- Added 'advance the commercialization of our approved product and the' before 'development and commercialization' in financing statement (2026-05-07 filing)
- Removed:
- Removed reference to 'May 2025 RTF letter received from the FDA' and related FDA meeting details about RCT requirement (2025-11-05 filing had this; 2026-05-07 filing removed it)
- Removed 'or to complete' after reference to potential new RCT in FDA response statement (2025-11-05 filing)
- Removed 'whether the NCCN will review and/or approve our submission for BCG-unresponsive NMIBC papillary' statement (2025-11-05 filing)
- Removed 'the timing of the development and commercialization of our other product candidates' as separate bullet point (2025-11-05 filing)
- Removed 'our ability to attract additional third-party collaborators' (2025-11-05 filing)
- Removed 'our expectations regarding the timing of enrollment and submission of our clinical trials, and protocols and timing of data read-outs related to such trials' (2025-11-05 filing)
- Removed 'our plans regarding our manufacturing facilities and our belief that our manufacturing is capable of being conducted in‑house' (2025-11-05 filing)
- Removed 'the rate and degree of market acceptance of any approved products' as separate bullet point (2025-11-05 filing)
- Removed reference to 'our ability to meet our payment obligations under the RIPA and to service the interest on our related-party promissory note' (2025-11-05 filing)
- Reworded:
- Changed 'NMIBC papillary' to 'NMIBC with CIS, with papillary tumors' in indications language (2026-05-07 filing)
- Changed 'as a lymphopenia rescue agent' to 'as a lymphopenia rescue agent in solid tumors or other indications' (2026-05-07 filing)
- Changed 'complete the commercialization' to 'advance the commercialization' (2026-05-07 filing)
- Changed 'our strategy and technology' to include 'Cancer BioShield platform (comprises multiple therapeutic modalities to activate immune response) and our strategy and technology' (2026-05-07 filing)
- Changed 'warrant and derivative values' to 'warrant, derivative, and fair value accounting measurement values' (2026-05-07 filing)
- Changed 'our product candidates' to 'our approved product and product candidates' in multiple references (2026-05-07 filing)
- Changed 'BCG-unresponsive NMIBC papillary' to 'BCG-unresponsive NMIBC with papillary tumors' (2026-05-07 filing)
- Changed 'aNK and haNK' to 'aNK, haNK, taNK, and NK-CAR (t-haNK)' in Phase 1/2 clinical trials reference (2026-05-07 filing)
- Changed language from 'may have concerns' to 'successfully address any concerns' regarding FDA sBLA (2026-05-07 filing)
- Changed 'our product candidates' to 'our approved product and product candidates' in manufacturing and distribution statements (2026-05-07 filing)
- Notes:
- The newer filing (2026-05-07) appears to be truncated at the end and does not include the full MD&A section provided in the older filing (2025-11-05), making a complete comparison of all removals potentially incomplete
- Some changes reflect updates to product candidate pipeline descriptions and regulatory status rather than material financial or operational changes
Risk Factors
- Added:
- Added phrase 'including for efforts to obtain approval for additional indications' to first financial condition risk factor (filed 2026-05-07)
- Added 'obtain approval for additional indications,' to second product development risk factor (filed 2026-05-07)
- Added phrase 'or us' to third-party reliance risk factor first bullet (filed 2026-05-07)
- Added 'ANKTIVA' as specific product name in third-party reliance first bullet (filed 2026-05-07)
- Added references to 'the SFDA, and the ISAF of the Macau Special Administrative Region of the People's Republic of China and have been granted conditional marketing authorization from the EC (EMA) for the EU' in regulatory approval risk factor (filed 2026-05-07)
- Added 'promoting and other' phrase in regulatory requirements risk factor (filed 2026-05-07)
- Removed:
- Removed 'vertically-integrated commercial stage' descriptor from first financial condition risk factor (filed 2025-11-05)
- Removed 'including for efforts to obtain approval for additional indications' from second financial condition risk factor (filed 2025-11-05)
- Removed reference to 'ANKTIVA internationally' and 'ANKTIVA or' from third-party reliance first bullet (filed 2025-11-05)
- Removed 'or us' from third-party reliance first bullet (filed 2025-11-05)
- Removed references to 'the SFDA, and the ISAF of the Macau Special Administrative Region of the People's Republic of China and have been granted conditional marketing authorization from the EC (EMA) for the EU' from regulatory approval risk (filed 2025-11-05)
- Removed 'and the MHRA' reference, replacing with expanded regulatory approval list (filed 2025-11-05)
- Removed sentence 'We are, and will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.' from regulatory approval risk factor (filed 2025-11-05)
- Removed 'and we may engage in disputes with such third parties, which can be costly and time consuming' from strategic alliances risk factor (filed 2025-11-05)
- Removed 'promoting and other' phrase leaving just 'labeling' in regulatory requirements risk factor (filed 2025-11-05)
- Reworded:
- Changed 'We are a biotechnology company' to remove 'vertically-integrated commercial stage' descriptor (filed 2026-05-07 vs 2025-11-05)
- Changed 'to conduct the clinical trials according' to 'to conduct clinical trials according' in third-party reliance bullet (filed 2026-05-07)
- Changed 'our approved product, to seek or obtain regulatory approval for or commercialize our other product candidates' to 'ANKTIVA internationally, to seek or obtain incremental regulatory approvals for ANKTIVA or our other product candidates' (filed 2026-05-07)
- Changed regulatory approval statement from 'While we have one product approved by the FDA and the MHRA' to comprehensive list including SFDA, ISAF, and EMA (filed 2026-05-07)
- Changed risk factor structure by separating and reordering regulatory approval and regulatory requirements risk factors (filed 2026-05-07)
- Notes:
- Text of older filing appears truncated at end ('Risks Related to Our Common Stock' section incomplete), limiting full comparison of later risk factors
- Newer filing text also appears to end abruptly mid-word ('Ri'), suggesting potential truncation
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($1M) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 2 sells ($1M) — 2 selling insiders
- Last 180 days · read to 2026-10-040 buys · 8 sells ($5M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IBRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IBRX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 67,889,882
- Reported value $594,375,918
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IBRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IBRX had 125,408,192 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IBRX had 11.8% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.86 days to cover at the same settlement.
- Reported short interest (shares) 125,408,192
- Short interest (% of shares outstanding) 11.8%
- Prior settlement (shares) 125,637,933
- Reported change -0.18%
- Days to cover (reported) 15.86
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
- AstraZeneca (AZN)
- Gilead Sciences (GILD)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IBRX vs…
IMMUNITYBIO INC is found in…
IBRX ranks in…
Frequently asked questions
What does IMMUNITYBIO INC (IBRX) do?
ImmunityBio is a clinical-stage biotechnology company focused on developing therapies and vaccines that activate the human immune system to fight cancers and infectious diseases. Its core technology, the Cancer BioShield platform, utilizes multiple therapeutic modalities, including immunotherapy, cell therapy, and vaccines, to induce broad-based immune responses. The company's lead product, ANKTIVA, is an IL-15 superagonist approved for specific bladder cancer indications.
What sector is IMMUNITYBIO INC (IBRX) in?
IMMUNITYBIO INC (IBRX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are IMMUNITYBIO INC's (IBRX) competitors?
Notable peers of IMMUNITYBIO INC (IBRX) include Merck, Bristol Myers Squibb, Roche, AstraZeneca and Gilead Sciences. This peer set is informational only — not financial advice.
Is IMMUNITYBIO INC (IBRX) overbought or oversold right now?
IMMUNITYBIO INC (IBRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IBRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.